Portfolio
Strategy
Team
News
Careers
Contact
Investor Login
Portfolio
Strategy
Team
News
Careers
Contact
Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors
Read Article
News
2024
2023
Archive
Search news articles
September 27, 2017
FDA SELECTS PARTICIPANTS FOR NEW DIGITAL HEALTH SOFTWARE PRE-CERTIFICATION PILOT PROGRAM; INCLUDES PEAR THERAPEUTICS
September 27, 2017
AUDENTES THERAPEUTICS ANNOUNCES RARE PEDIATRIC DISEASE AND FAST TRACK DESIGNATIONS FOR AT132 FOR THE TREATMENT OF X-LINKED MYOTUBULAR MYOPATHY
September 21, 2017
AUDENTES THERAPEUTICS ANNOUNCES DOSING OF FIRST PATIENT IN ASPIRO, A PHASE 1/2 CLINICAL TRIAL OF AT132 FOR THE TREATMENT OF X-LINKED MYOTUBULAR MYOPATHY
September 20, 2017
ARVINAS APPOINTS DR. JOHN HOUSTON AS PRESIDENT AND CHIEF EXECUTIVE OFFICER
September 15, 2017
PEAR THERAPEUTICS OBTAINS FDA CLEARANCE OF THE FIRST PRESCRIPTION DIGITAL THERAPEUTIC TO TREAT DISEASE
September 7, 2017
CRINETICS PHARMACEUTICALS AWARDED TWO SBIR GRANTS TO DEVELOP NEW THERAPEUTICS FOR CONGENITAL HYPERINSULINISM AND CUSHING’S DISEASE
August 29, 2017
RARECYTE COMPLETES $30M PRIVATE FINANCING FOR COMMERCIAL EXPANSION OF RARE CELL DETECTION TECHNOLOGY FOR LIQUID BIOPSIES
August 11, 2017
VIVEVE ANNOUNCES SECOND QUARTER 2017 FINANCIAL RESULTS AND STRATEGIC PARTNERSHIP WITH INCONTROL MEDICAL, LLC
August 11, 2017
VIVEVE ANNOUNCES SECOND QUARTER 2017 FINANCIAL RESULTS AND STRATEGIC PARTNERSHIP WITH INCONTROL MEDICAL, LLC
August 8, 2017
APREA THERAPEUTICS ANNOUNCES FIRST PATIENT ENROLLED IN PHASE IB/II CLINICAL STUDY OF APR-246 FOR THE TREATMENT OF PLATINUM-RESISTANT HIGH-GRADE SEROUS OVARIAN CANCER
« Previous Page
1
…
68
69
70
71
72
…
103